Financial Data and Key Metrics Changes - AbbVie reported full-year adjusted earnings per share of $10, exceeding initial guidance by $0.54, and total net revenues of $61.2 billion, surpassing guidance by over $2 billion [4][5] - Sales growth of 8.6% led to record net sales, exceeding previous peak revenue by more than $3 billion despite nearly $16 billion erosion from U.S. Humira [5][6] - Adjusted earnings per share for Q4 were $2.71, $0.08 above guidance midpoint, with total net revenues of $16.6 billion reflecting robust growth of 10% [33][34] Business Line Data and Key Metrics Changes - Immunology revenues reached approximately $8.6 billion in Q4, with Skyrizi sales of $5 billion (31.9% operational growth) and Rinvoq sales of nearly $2.4 billion (28.6% operational growth) [10][11] - Neuroscience full-year revenues exceeded $10.7 billion, with Q4 revenues of over $2.9 billion (17.3% operational growth), driven by Vraylar and Botox Therapeutic [17][18] - Oncology revenues were nearly $1.7 billion in Q4, down 2.5% operationally, with Venclexta sales of $710 million (6.4% operational growth) [19][20] Market Data and Key Metrics Changes - Global sales for Skyrizi in IBD reached approximately $6.4 billion in 2025, more than double the prior year's performance [13] - Humira delivered global sales of over $1.2 billion, down 26.1% operationally due to biosimilar competition [17] - The aesthetics segment saw global sales of nearly $1.3 billion in Q4, down 1.2% operationally, with Botox Cosmetic revenues of $717 million (3.8% operational growth) [20][21] Company Strategy and Development Direction - AbbVie plans to deliver total sales growth of 9.5% in 2026, driven by Skyrizi and Rinvoq, with combined sales expected to exceed $31 billion [6][7] - The company is focused on advancing its pipeline with significant investments in R&D, including over $5 billion in new business development [5][6] - A voluntary agreement with the U.S. government aims to enhance patient access and affordability while committing $100 billion in U.S. R&D and capital investments over the next decade [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in AbbVie's strong position to deliver high single-digit revenue growth through 2029, despite headwinds from Humira erosion and Imbruvica pricing [6][9] - The company anticipates key catalysts in R&D across immunology, neuroscience, and oncology over the next 24 months [8][9] - Management highlighted the potential for sustained long-term growth driven by innovative therapies and strategic acquisitions [9][10] Other Important Information - AbbVie increased adjusted R&D expense by nearly $1 billion in 2025, fully funding 90 clinical programs currently in development [5][6] - The company expects to generate free cash flow of approximately $18.5 billion in 2026, supporting a strong and growing quarterly dividend [39][40] Q&A Session Summary Question: Details on the psychedelic therapy in development - Management highlighted the potential of the psychedelic therapy to provide immediate efficacy with a short-acting profile, aiming for a breakthrough in treatment [41][42] Question: Insights on Skyrizi in IBD and market expectations - Management confirmed stable new patient starts for Skyrizi in both Crohn's and UC, with high capture rates despite competition [44][46] - They expressed confidence in the long-term growth potential for Skyrizi and Rinvoq, indicating that current market models may not fully reflect this upside [48][49] Question: Update on external innovation and business development - AbbVie has invested over $8 billion in external innovation, focusing on early-stage opportunities to drive growth in immunology, neuroscience, and oncology [52][54] Question: Expectations for Rinvoq and Lutikizumab phase 3 data - Management emphasized the importance of upcoming studies for Rinvoq and Lutikizumab, particularly in treatment failure populations, and expressed optimism based on previous performance [55][56]

Core Insights - AbbVie reported higher fourth-quarter revenue driven by growth in its immunology portfolio, particularly from arthritis and Crohn's disease drugs Skyrizi and Rinvoq [1] Revenue Growth - The increase in revenue is attributed to the strong performance of the immunology drugs, which have seen significant demand in the market [1]

AbbVie posts better-than-expected earnings but revenue declines across certain business lines. ...

AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-th... ...

Core Insights - AbbVie reported strong financial results for the fourth quarter and full year of 2025, with a notable increase in net revenues and adjusted diluted EPS guidance for 2026 [1] Financial Performance - Fourth-quarter net revenues reached $16.618 billion, marking a 10.0% increase on a reported basis and 9.5% on an operational basis [1] - Full-year net revenues totaled $61.160 billion, an increase of 8.6% on a reported basis and 8.5% on an operational basis [1] - Fourth-quarter diluted EPS was $1.02 on a GAAP basis, while adjusted diluted EPS was $2.71, reflecting an unfavorable impact of $0.71 per share from acquired IPR&D and milestones expense [1] Portfolio Performance - The immunology portfolio generated global net revenues of $30.406 billion for the full year, an increase of 14.0% on a reported basis [1] - The neuroscience portfolio saw a 19.6% increase in global net revenues, totaling $10.767 billion for the full year [1] - The oncology portfolio reported full-year global net revenues of $6.655 billion, a slight increase of 1.5% on a reported basis [1] - The aesthetics portfolio experienced a decline, with full-year global net revenues of $4.860 billion, down 6.1% on a reported basis [1] Recent Developments - AbbVie announced the acquisition of a device manufacturing facility from West Pharmaceutical Services to enhance production capabilities for immunology and neuroscience medicines [1] - An exclusive licensing agreement was established with RemeGen for the development of a novel bispecific antibody, RC148, aimed at treating advanced solid tumors [1] - AbbVie received FDA approval for Epkinly in combination with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma [1] - The company submitted applications for expanded use of Aquipta for migraine treatment and for Rinvoq in treating non-segmental vitiligo [1] 2026 Outlook - AbbVie provided adjusted diluted EPS guidance for 2026 in the range of $14.37 to $14.57, excluding any unfavorable impacts from acquired IPR&D and milestones [1]

Market Overview - The US stock market experienced a decline, with the Chinese concept index dropping by 0.94%. The Hang Seng Index fell by 110.27 points, a decrease of 0.41%, closing at 26,724.50 points, while the Hang Seng Tech Index dropped by 120.19 points, down 2.20%, reaching a new low since mid-July 2025 [1] - Technology stocks, particularly those considered riskier, continued to decline, with Tencent falling nearly 4% after restrictions on its "Yuanbao Red Packet" link by WeChat. Other major players like Baidu, Meituan, and Xiaomi also saw declines of over 2%, while Bilibili dropped nearly 5% [1] - Chip stocks faced significant losses, with Shanghai Fudan down nearly 9%, Huahong Semiconductor down over 5%, and SMIC down nearly 3% [1] - The coal sector showed strength, with Feishang No Smoke Coal rising over 33%. Real estate stocks also performed well, with Sunac China up over 7% and China Resources Land up nearly 4% [1] Corporate Developments - In the technology sector, InnoCare successfully completed a significant design integration for AI hardware with Google, establishing a solid foundation in the AI hardware market [1] - Enoch Intelligent received a milestone payment of HKD 39 million from Menarini, marking a significant step in its pharmaceutical technology research [1] - Capital investment firm Shumeng Capital signed a contract worth USD 3 million with a Macau distributor, expanding its business footprint [1] Pharmaceutical Industry Highlights - Youzhiyou Biotech's M701 received FDA IND approval for a novel therapy targeting malignant pleural effusion, marking a new phase in international clinical development [2] - Xiansheng Pharmaceutical received a milestone payment of USD 40 million from AbbVie for the overseas licensing option agreement for SIM0500, highlighting its competitiveness in the international pharmaceutical market [2] - Kangfang Biotech granted exclusive commercialization rights for Yixinning® to Jichuan Pharmaceutical, resulting in significant licensing fees and milestone payments [2] - Federal Pharmaceuticals' UBT251 injection received implied clinical trial approval for a new indication, providing new treatment options for patients [2] Food Industry Performance - Nissin Foods reported strong performance in its China business segment, with revenue reaching JPY 54.948 billion, a year-on-year increase of 2.7%, and core operating profit of JPY 5.859 billion, up 9.3% [2] Capital Market Insights - Guotai Junan International noted a market shift from "liquidity-driven" to "profit-driven" dynamics, suggesting a focus on fundamental analysis rather than speculative trading [4] - CITIC Securities observed significant adjustments in Hong Kong stock earnings expectations, predicting a continuation of the spring market rally with large-cap stocks outperforming [4] - Huatai Securities indicated that the current market sentiment has shifted to optimism, suggesting a focus on companies with earnings certainty and potential for growth in technology and cyclical sectors [5] - Guoyuan International highlighted that Hong Kong stocks may continue to outperform US stocks due to favorable conditions for non-US assets and the potential recovery of domestic demand [5]

Core Viewpoint - AbbVie and Medtronic are highlighted as healthcare stocks that consistently grow their dividends, supported by healthy free cash flow, despite the general trend of lower dividend yields in the healthcare sector [1][3][15]. AbbVie - AbbVie has a dividend yield of 2.98% and has increased its quarterly dividend for 54 consecutive years, qualifying it as a Dividend King [4]. - The company reported revenue of $15.8 billion in the third quarter, a 9% year-over-year increase, although earnings per share (EPS) declined by 38% to $1.86 due to higher R&D spending [6]. - AbbVie has successfully transitioned from reliance on Humira, which previously accounted for 63% of its revenue, to a diversified portfolio including Rinvoq and Skyrizi, with Skyrizi generating $4.7 billion in the latest quarter [7]. - The oncology segment now contributes nearly 11% to AbbVie's revenue, bolstered by new therapies [8]. - AbbVie's dividend payout ratio is 58%, but its free cash flow per share of $11.11 supports its annual dividend payout of $6.92 [9]. Medtronic - Medtronic, with a market cap of $132 billion, is the largest stand-alone medical device maker, producing a wide range of medical equipment [10]. - The company reported revenue of $9 billion in the second quarter of fiscal 2026, a 6.6% year-over-year increase, with EPS rising 8% to $1.07 [13]. - Medtronic's dividend yield is approximately 2.76%, and it has increased its dividend for 48 consecutive years, with a payout ratio of 69% [14]. - The company plans to spin off its diabetes business, which accounts for only 8% of revenue, without impacting its dividend [14]. Industry Insights - Healthcare companies, unlike utilities, must continuously invest in R&D due to the nature of their products, which often face patent expirations and generic competition [2]. - AbbVie and Medtronic leverage their size and diversification to maintain revenue growth and dividend increases, mitigating risks from potential downturns in specific segments [15][16].

Group 1 - AstraZeneca PLC is recognized for its strong cancer franchise and is recommended to hold by Jim Cramer, who believes it has a better portfolio compared to AbbVie at this moment [1] - AstraZeneca is one of the largest pharmaceutical companies globally, focusing on oncology, cardiovascular, respiratory, and rare diseases, with a robust on-market portfolio and a leading late-stage pipeline [2] - The company is led by CEO Pascal Soriot, noted for his exceptional management and innovative culture, which is expected to drive strong growth in the future [2] Group 2 - Recent regulatory concerns in the United States have overshadowed AstraZeneca's strengths, creating an opportunity for investors to acquire shares below their intrinsic value [2]

Major Events - InnoCare Pharma (09926) granted exclusive commercialization rights of Yixineng® to Jichuan Pharmaceutical [1] - Ying Si Intelligent (03696) received a milestone payment of HKD 39 million from Menarini, with the MEN2501 project completing its first patient dosing [1] - Xiansheng Pharmaceutical (02096) received a recent milestone payment related to the overseas licensing option agreement for SIM0500 with AbbVie [1] - Innovent Biologics (02577) completed significant design integration for related products on Google's AI hardware platform and signed a compliant supply agreement [1] - Federal Pharmaceutical (03933) obtained implied approval for clinical trials of UBT251 injection for OSA indications [1] - Kanghong Pharmaceutical (00867) received clinical trial approval for the innovative drug CMS-D017 capsule for complement-mediated kidney disease indications [1] - First Capital Holdings (00697) announced the successful IPO and listing of Shimon Holdings on the Shenzhen Stock Exchange [1] Operating Performance - Country Garden (02007) achieved a contract sales amount of approximately CNY 2.21 billion attributable to shareholders by January 2026 [1] - Nissin Foods (01475) reported an operating profit of JPY 5.672 billion from its China business segment for the first three quarters, representing a year-on-year increase of 99.8% [1] - Natural Beauty (00157) issued a profit warning, expecting an annual net profit of approximately HKD 8 million to HKD 10 million, marking a turnaround from losses [1]

Core Insights - Allergan Aesthetics, a subsidiary of AbbVie, has launched the Faces of Natrelle Testimonial Program to encourage women to share their experiences with Natrelle breast implants, aiming to educate and empower others considering breast surgery [1][2][6] Group 1: Program Overview - The Faces of Natrelle initiative invites women aged 22 and older who have undergone breast augmentation or reconstruction to submit testimonials, photos, or videos to be featured on various platforms [2][3] - The program aims to address misconceptions surrounding breast procedures and promote transparency and empowerment among women [2][3] Group 2: Participant Incentives - Participants who share their experiences may be eligible to receive $500 in All Gift Cards if their content is approved, while reconstruction patients are encouraged to share their stories without compensation [4][8] - The program emphasizes the importance of sharing personal journeys to provide clarity and confidence to others [3][6] Group 3: Company Background - Allergan Aesthetics develops and markets a range of aesthetic products, including breast implants, and is committed to innovation and education in the aesthetics field [19] - AbbVie, the parent company, focuses on delivering innovative medicines and solutions across various therapeutic areas, including aesthetics [20]